Epivir HBV
Epivir HBV Price range: $ 53,00 through $ 360,00
Back to products
Eriacta
Eriacta Price range: $ 62,00 through $ 427,00

Erectafil

Price range: $ 60,00 through $ 466,00

Erectafil is a highly effective medication specifically designed to treat erectile dysfunction in men. Containing Tadalafil as its active ingredient, this formula works by increasing blood flow to specific areas of the body to support a firm and lasting response. Users often prefer this solution because it provides a reliable window of effectiveness, allowing for greater spontaneity in intimate moments. The treatment is available in convenient tablet form and is engineered for efficient absorption to help achieve the desired results. By restoring natural performance, Erectafil helps men regain their confidence and maintain a satisfying quality of life.

Active substance: Tadalafil
SKU: Erectafil Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Erectafil belongs to the class of phosphodiesterase type 5 (PDE5) inhibitors, containing tadalafil as its active pharmaceutical ingredient. In the United States, medications containing tadalafil are classified as prescription drugs and are dispensed in accordance with applicable federal and state regulations under appropriate medical supervision.

The medication is indicated primarily for the treatment of erectile dysfunction and the lower urinary tract symptoms secondary to benign prostatic hyperplasia. Clinical evaluation by a qualified healthcare practitioner is required to determine appropriate dosing, assess cardiovascular readiness, and evaluate potential drug-drug interactions prior to initiating therapy.

Parameter Specification
Active Ingredient Tadalafil
Therapeutic Class Phosphodiesterase Type 5 (PDE5) Inhibitor
Dosage Form Oral Tablet
Route of Administration Oral
Primary Purpose Erectile Dysfunction, Benign Prostatic Hyperplasia
Prescription Status Prescription (Rx) only
Storage Conditions Store at 20°C to 25°C (68°F to 77°F)

Clinical Overview and Pharmacological Profile

How the drug works

Tadalafil acts as a selective and potent reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). During local sexual stimulation, nitric oxide is released from nerve endings and vascular endothelial cells within the corpus cavernosum of the penis. Nitric oxide stimulates the enzyme guanylate cyclase, resulting in increased cellular levels of cGMP. Elevated cGMP induces smooth muscle relaxation and increased blood flow into the cavernous tissues, enabling an erection. By selectively inhibiting PDE5, tadalafil prevents the enzymatic degradation of cGMP, thereby sustaining the physiological erectile response. In the vascular smooth muscle of the prostate gland and urinary bladder, PDE5 inhibition similarly reduces smooth muscle tone, mitigating urinary outflow resistance associated with benign prostatic hyperplasia. Sexual stimulation is mandatory to initiate the endogenous nitric oxide cascade; tadalafil produces no erectile effect in the absence of sexual arousal.

Main uses

The primary clinical indication for tadalafil is the management of erectile dysfunction (ED) in adult males. Additionally, once-daily administration is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH), as well as the concurrent management of ED and BPH in patients presenting with both conditions. Any therapeutic application outside of these FDA-approved indications–such as off-label protocols for arterial vasodilation or exercise capacity enhancement–must be explicitly designated as off-label and requires rigorous individualized medical assessment by a licensed provider.

Dosing schedule

Dosing regimes are determined strictly by the prescribing healthcare provider based on the clinical indication and patient response. For on-demand treatment of erectile dysfunction, the standard starting dose is 10 mg taken orally prior to anticipated sexual activity. Based on individual efficacy and tolerability, the dose may be titrated to 20 mg or decreased to 5 mg. The maximum recommended dosing frequency for on-demand use is once daily. For continuous once-daily therapy in ED or BPH, the recommended regimen is 2.5 mg to 5 mg taken at approximately the same time each day without regard to the timing of sexual activity. Patient populations with moderate to severe renal impairment or hepatic impairment require reduced dosage protocols, often restricted to a maximum of 10 mg on-demand every 48 to 72 hours.

What happens in the body

Following oral administration, tadalafil is rapidly absorbed, attaining peak median plasma concentrations ($C_{max}$) within 0.5 to 6 hours (median time of 2 hours). The absolute bioavailability of tadalafil after oral administration has not been fully elucidated. The rate and extent of absorption are not meaningfully altered by food intake, allowing administration with or without meals. Tadalafil exhibits wide tissue distribution, with a mean apparent volume of distribution of approximately 63 liters, and is approximately 94% bound to plasma proteins. Metabolism occurs predominantly in the liver via the cytochrome P450 3A4 (CYP3A4) enzymatic pathway, yielding circulating metabolites that are pharmacologically inactive. The mean terminal elimination half-life is approximately 17.5 hours in healthy adult males, supporting an extended duration of therapeutic action up to 36 hours. Elimination occurs primarily as inactive metabolites via the feces (approximately 61%) and to a lesser extent via urine (approximately 36%).

First days of treatment

When initiating tadalafil therapy, patients must understand the physiological timeframe governing its pharmacokinetic profile. For on-demand regimens, therapeutic activity generally becomes manifest between 30 and 60 minutes following ingestion, with peak systemic concentration occurring around 2 hours. For daily low-dose administration, steady-state plasma concentration is achieved within 5 consecutive days of continuous daily dosing. Mild self-limiting physiological adjustments, such as transient facial flushing or low-grade headache, may occur during initial exposures as vascular smooth muscle responds to PDE5 inhibition.

Signs of improvement

Therapeutic efficacy in erectile dysfunction is evaluated by an improved capacity to achieve and maintain a penile erection adequate for satisfactory sexual activity following sensory or psychological stimulation. In patients treated for benign prostatic hyperplasia, efficacy is identified by a reduction in lower urinary tract symptom scores, reflected by increased peak urinary flow rate, decreased urinary hesitancy, and reduced nocturnal micturition frequency. A lack of initial response during the first few attempts does not automatically indicate treatment failure; clinical protocol typically advises evaluating effectiveness over multiple distinct attempts under optimal therapeutic conditions.

Safety Guidelines, Precautions, and FAQs

Food and alcohol interactions

Tadalafil may be administered independently of food intake, as high-fat meals do not significantly alter total systemic exposure ($AUC$) or peak plasma concentration. However, substantial alcohol consumption (defined as blood alcohol levels of 0.08% or greater, equivalent to approximately 5 units of alcohol) in combination with tadalafil increases the potential for orthostatic hypotension. Concurrent heavy alcohol ingestion may induce transient blood pressure reductions, compensatory tachycardia, dizziness, and postural lightheadedness. Patients should exercise caution and limit alcohol consumption while taking this medication.

Compatibility with other medicines

Co-administration of tadalafil with organic nitrates in any pharmaceutical formulation (including nitroglycerin, isosorbide dinitrate, isosorbide mononitrate) or illicit nitric oxide donors (“poppers”) is strictly contraindicated. Concomitant use can precipitate acute, severe, and potentially fatal systemic hypotension. Co-administration with alpha-adrenergic blockers (such as tamsulosin or doxazosin) requires clinical caution and stabilized baseline blood pressure prior to initiation, as additive vasodilatory effects may result in symptomatic hypotension. Potent inhibitors of CYP3A4 (including ketoconazole, itraconazole, clarithromycin, and ritonavir) markedly increase systemic tadalafil exposure; dosage adjustments limiting single doses to 10 mg every 72 hours are indicated. Conversely, strong CYP3A4 inducers (such as rifampin, carbamazepine, and phenytoin) accelerate clearance and significantly lower tadalafil plasma concentrations, potentially diminishing therapeutic efficacy.

Adverse reactions

Adverse events associated with tadalafil administration are generally mild to moderate in severity and tend to decrease in incidence with continued therapy. Common adverse reactions reported in clinical trials include headache, dyspepsia, back pain, myalgia, nasal congestion, facial flushing, and pain in extremity. Myalgia and back pain typically manifest 12 to 24 hours following administration and generally resolve within 48 hours. Rare but medically significant adverse events require immediate emergency intervention; these include priapism (a painful erection lasting longer than 4 hours), sudden decrease or loss of vision attributed to non-arteritic anterior ischemic optic neuropathy (NAION), and sudden loss or decrease in hearing, occasionally accompanied by tinnitus and dizziness.

Storage and expiration

Tadalafil tablets must be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F), with permitted excursions between 15°C and 30°C (59°F to 86°F) in accordance with United States Pharmacopeia (USP) guidelines. Keep the medication in its original container to protect tablets from excessive ambient moisture and direct light exposure. Store safely out of the reach of children and domestic pets. Unused or expired medications must not be disposed of via household wastewater systems; utilize established local pharmacy take-back programs for safe environmental disposal.

Important precautions

Prior to prescribing tadalafil, a thorough cardiovascular evaluation is required, as sexual exertion entails an inherent cardiac risk for patients with pre-existing cardiovascular disease. Tadalafil is not recommended for individuals who have experienced a myocardial infarction within the past 90 days, those with unstable angina, severe heart failure (NYHA Class II or greater within the preceding 6 months), uncontrolled cardiac arrhythmias, severe hypotension (<90/50 mm Hg), uncontrolled hypertension, or a stroke within the past 6 months. In patients with severe renal impairment (creatinine clearance <30 mL/min), once-daily administration is not recommended, and on-demand dosing must not exceed 5 mg once every 72 hours. Tadalafil is not indicated for pediatric populations or female patients.

Common Questions

What should be done if a scheduled daily dose of tadalafil is missed?

If a patient on a once-daily dosing protocol misses a dose, the missed tablet should be taken as soon as it is remembered on that day. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients must never double the dose or take two doses in a single day to compensate for a missed tablet.

Does tadalafil produce a continuous erection for 36 hours?

No. Tadalafil does not cause an uninterrupted erection. The 36-hour therapeutic window refers to the duration during which the active ingredient remains present in the systemic circulation at levels sufficient to facilitate an erectile response when natural sexual stimulation occurs. An erection will subside naturally following sexual activity.

Is it safe to drive or operate machinery after taking this medication?

While tadalafil has no direct central nervous system sedative effects, clinical trials have reported instances of dizziness and visual disturbances. Patients should observe their individual physical response to tadalafil before driving, operating heavy machinery, or engaging in potentially hazardous tasks that require complete alertness.

How does impaired renal function alter tadalafil clearance?

Renal clearance plays a secondary role in total tadalafil elimination, but reduced kidney function increases overall systemic exposure ($AUC$) and extends the elimination half-life. Consequently, dosage caps (such as a maximum 5 mg or 10 mg dose with extended dosing intervals) are required for individuals with moderate to severe renal insufficiency to prevent drug accumulation.

Why is concurrent nitrate therapy strictly prohibited with tadalafil?

Nitrates increase cyclic GMP production through nitric oxide donation, while tadalafil blocks cGMP breakdown via PDE5 inhibition. When used simultaneously, these two mechanisms synergize to produce massive cGMP accumulation in vascular smooth muscle cells. This leads to profound vasodilation and a precipitate, potentially fatal drop in systemic blood pressure.

Information on this page is for reference and does not replace an assessment by a licensed healthcare professional. In accordance with FDA regulatory guidelines for prescription drug disclosures.

Additional information
Dosage

20mg

Package

30 pills

,

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία